The FDA has removed the previous requirement for blood tests before prescribing clozapine, the only medication approved for treatment-resistant schizophrenia. This change aims to improve access to a drug that is recognized as highly effective but has been underutilized due to bureaucratic hurdles. Despite evidence that clozapine significantly benefits many patients, currently only 4% of those who could use it have access. Experts believe up to 30% of schizophrenia patients could improve with clozapine, leading to better quality of life and reduced hospitalization.
Clozapine, the only drug approved for treatment-resistant schizophrenia, has long been underutilized due to stringent blood testing requirements that the FDA is now eliminating.
Many physicians regard clozapine as the most effective treatment for schizophrenia, significantly reducing suicidal behavior, yet it's prescribed to only 4% of eligible patients.
Dr. Frederick C. Nucifora emphasizes that clozapine allows patients struggling with severe schizophrenia to regain functionality, highlighting its transformative impact on their lives.
Collection
[
|
...
]